Quanterix Corporation logo QTRX - Quanterix Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 5
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $4.00 DETAILS
HIGH: $4.00
LOW: $4.00
MEDIAN: $4.00
CONSENSUS: $4.00
UPSIDE: 48.70%

Stock News

Quanterix Announces Planned Transition of Chief Financial Officer

Quanterix Announces Planned Transition of Chief Financial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (“CFO”) will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition. "Vandana has made impactful contributions to Quanterix since joining the Co.

May 12, 2026 12:01 PM • businesswire.com
Quanterix Releases Financial Results for the First Quarter of 2026

Quanterix Releases Financial Results for the First Quarter of 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. “We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition,” said Everett Cunningham, President & CEO of Quanterix. “As part.

May 06, 2026 12:01 PM • businesswire.com
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing.

May 06, 2026 04:00 AM • businesswire.com
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. T.

Apr 24, 2026 04:33 AM • businesswire.com
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer, was developed on Akoya PhenoImager® HT platform using Opal™ chemistry. This marks a significant milestone in the clinical translation of spatial proteomics. The validation of AidaBREAST included 922 hormone recep.

Apr 17, 2026 04:33 AM • businesswire.com
Quanterix Debuts Content Innovation Engine at AACR 2026

Quanterix Debuts Content Innovation Engine at AACR 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration of Akoya Biosciences' spatial biology platform and Quanterix's decades of ultra-sensitive, quantitative immunoassay development from the SIMOA® technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a sys.

Apr 15, 2026 04:33 AM • businesswire.com
Quanterix Corporation Announces Date of 2026 Annual Meeting

Quanterix Corporation Announces Date of 2026 Annual Meeting

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Company's 2026 annual meeting of shareholders (the “Annual Meeting”) will be held virtually, by means of remote communication, on Tuesday, June 9, 2026 at 10:00 am Eastern Time. Stockholders of record of the Company's common stock as of the close of business on April 14, 2026 will be entitled to vote.

Mar 27, 2026 12:00 PM • businesswire.com
Analyzing Quanterix (NASDAQ:QTRX) & IM Cannabis (NASDAQ:IMCC)

Analyzing Quanterix (NASDAQ:QTRX) & IM Cannabis (NASDAQ:IMCC)

Quanterix (NASDAQ: QTRX - Get Free Report) and IM Cannabis (NASDAQ: IMCC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Institutional and Insider Ownership 86.5% of Quanterix shares

Mar 18, 2026 10:14 PM • defenseworld.net
Quanterix (NASDAQ:QTRX) vs. TREES (OTCMKTS:CANN) Head-To-Head Review

Quanterix (NASDAQ:QTRX) vs. TREES (OTCMKTS:CANN) Head-To-Head Review

TREES (OTCMKTS:CANN - Get Free Report) and Quanterix (NASDAQ: QTRX - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability. Profitability This table compares TREES and Quanterix's net margins,

Mar 08, 2026 09:30 PM • defenseworld.net
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. “I am thrilled to be joining Quanterix at a time when the company is well-positioned to deliver long-term growth,” said Everett Cunningham, President & CEO of Quanterix. “During the fourth quarter, we exceeded our revenue expectations, we con.

Mar 02, 2026 11:01 AM • businesswire.com
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the g.

Mar 02, 2026 03:33 AM • businesswire.com
Quanterix to Participate in Upcoming Investor Conferences

Quanterix to Participate in Upcoming Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March: 46th Annual TD Cowen Healthcare Conference Format: Fireside chat and one-on-one meetings Date: Wednesday, March 4, 2026 Time: 11:50 am ET Webcast: Click here Leerink Global Healthcare Conference 2026 Forma.

Feb 26, 2026 03:33 AM • businesswire.com
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026.

Feb 20, 2026 03:33 AM • businesswire.com
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer's disease (AD). This submission represents a significant milestone in the Company's mission to provide superior, non-invasive, high-performance diagnost.

Feb 03, 2026 03:33 AM • businesswire.com

Price Targets